SARS-CoV-2 Spike-specific T-cell receptor (Spike-specific TCR)

SARS-CoV-2 Spike-specific T-cell receptors (TCRs) are specialized protein complexes found on the surface of CD4+ and CD8+ T lymphocytes that mediate the cellular immune response against the SARS-CoV-2 virus (1.1.4, 1.3.1). These receptors function by recognizing specific peptide fragments of the viral Spike protein, which are presented by Major Histocompatibility Complex (MHC) molecules on the surface of infected cells or professional antigen-presenting cells (1.3.2, 1.3.3). Upon binding to a Spike epitope-MHC complex, the TCR triggers an intracellular signaling cascade that leads to T-cell activation, proliferation, and the execution of effector functions, such as the secretion of pro-inflammatory cytokines like interferon-gamma and the direct killing of virus-infected cells by CD8+ cytotoxic T cells (1.1.4, 1.2.1). These receptors are the primary targets of COVID-19 vaccines, which aim to expand the repertoire of Spike-specific T cells to provide long-term protection against severe disease (1.1.1, 1.1.3). In clinical research, Spike-specific TCRs serve as critical biomarkers for assessing vaccine efficacy and the breadth of the immune response across different viral variants (1.1.2, 1.3.4). Furthermore, they are being investigated as components of adoptive T-cell therapies for immunocompromised patients who cannot mount an effective endogenous immune response (1.2.1, 1.2.3).

Other names

SARS-CoV-2 Spike-specific TCRSpike-reactive T-cell receptorAnti-Spike TCRSpike-specific αβ TCRSARS-CoV-2 S-specific TCR

Recognition of Spike protein epitopes presented by MHC molecules, leading to T-cell activation and elimination of infected cells.